Effect of TRPA1 antagonist (ORM) in the STZ induced model of diabetic neuropathy:

Project: Consultancy

Project Details

Key findings

ORM NCE dose dependently (10-80mgkg po, single dose) reverses allodynia in STZ diabetic neuropathy model in line with Pregabalin and ORM positive control.
PKPD determined.

Identified the potential of targeting TRPA1 receptors in type 1 diabetic neuropathic pain.

Effective start/end date31/07/1730/08/17


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.